Jefferies Upgrades Chemed to Buy with Higher Price Target Following Earnings Beat
Jefferies has upgraded Chemed (CHE) from hold to buy, raising its price target from $520 to $620. This move follows a third-quarter earnings report that exceeded analyst expectations and signals the company's recovery from recent operating issues that had impacted earnings visibility. Analyst Brian Tanquilut suggests that Chemed is poised to regain its status as a defensive 'compounder' with a premium valuation. The upgrade highlights that the company has successfully navigated Medicare hospice cap constraints and that its Roto-Rooter plumbing segment is stabilizing after increased marketing expenditures.
Tickers: $CHE
Topics: Analyst Rating Change Earnings Beat Healthcare Services Stock Upgrade
Part of the story Jefferies Upgrades Chemed to Buy with Higher Price Target Following Earnings Beat (4 articles)